July 1, 2020 -- Luminex has delivered the xMap Intelliflex system, a new version of its multiplexed biological test platform, to several life science partners.
The new system can double the multiplex capabilities of the platform, enabling users to explore new applications, including the ability to use a dual-reporter that can simultaneously detect multiple COVID-19 antibodies in a single serology test, according to Luminex.
Other new features include touchscreen controls, an improved user interface, a streamlined setup, and better workflow control due to enhanced software. Improved optics and fluidics also enable designers to explore the development of more sensitive and robust xMap assays, according to the company.
Luminex plans to ship the technology to major research institutions and other partners during the third quarter and fully commercialize it by the end of the year.